Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
about
Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
P2860
Q39137457-CAAC20A2-35C9-47AF-B59C-6A54062B91E7Q39177442-D4FEEEDB-EE62-4264-A718-BCC62A168C4EQ39200835-F784F9FB-0399-47C9-A084-C0C73D974955Q45057327-C6A32FEC-D233-437D-9B43-E3C88D7DC159Q47610956-0240F8D2-1F7C-4031-BF3E-C5CCC05B4C8BQ48146110-68C1EA78-06A2-40F5-807D-24DD435DCD8CQ48257454-CBE4C7A9-C272-438B-B55A-76984EF49607Q49171317-6EEDD972-9408-49CF-8116-126AC47FE764Q50119590-D27A8E58-ABCE-4C77-8556-AD51EB4D36A5Q51007604-D23F0840-D619-454C-9BC7-4869A88A3438Q51280033-6E90425B-A4F9-4FE9-B590-B599F242F59E
P2860
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Impact of Venetoclax Exposure ...... Chronic Lymphocytic Leukemia.
@en
type
label
Impact of Venetoclax Exposure ...... Chronic Lymphocytic Leukemia.
@en
prefLabel
Impact of Venetoclax Exposure ...... Chronic Lymphocytic Leukemia.
@en
P2093
P2860
P1476
Impact of Venetoclax Exposure ...... Chronic Lymphocytic Leukemia.
@en
P2093
Ahmed Hamed Salem
Aksana K Jones
Doerthe Eckert
Kevin J Freise
Rod A Humerickhouse
Shekman L Wong
Sven Mensing
Walid M Awni
P2860
P2888
P304
P356
10.1007/S40262-016-0453-9
P577
2016-09-15T00:00:00Z
P6179
1011190437